4.7 Article

Evidence for different in vitro oligomerization behaviors of synthetic hIAPP obtained from different sources

Journal

ANALYTICAL AND BIOANALYTICAL CHEMISTRY
Volume 412, Issue 13, Pages 3103-3111

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s00216-020-02560-5

Keywords

Human amylin; Capillary electrophoresis; Ion mobility mass spectrometry; ThT fluorescence spectroscopy; Aggregation; Amyloid; Type 2 diabetes

Funding

  1. French National Research Agency (ANR) - IDEX Paris-Saclay [ANR-11-IDEX-0003-02]
  2. DIM analytics from the Region Ile de France

Ask authors/readers for more resources

Type 2 diabetes is characterized by the aggregation of human islet amyloid polypeptide (hIAPP), from monomer to amyloid deposits that are made of insoluble fibrils. Discrepancies concerning the nature of formed species or oligomerization kinetics among reported in vitro studies on hIAPP aggregation process have been highlighted. In this work, we investigated if the sample itself could be at the origin of those observed differences. To this aim, four hIAPP samples obtained from three different sources or suppliers have been analyzed and compared by ThT fluorescence spectroscopy and by two recently developed techniques, capillary electrophoresis (CE), and ESI-IMS-QToF-MS. Lots provided by the same supplier were shown to be very similar whatever the analytical technique used to characterize them. In contrast, several critical differences could be pointed out for hIAPP provided by different suppliers. We demonstrated that in several samples, some oligomerized peptides (e.g., dimer) were already present upon reception. Purity was also different, and the proneness of the peptide solution to form fibrils in vitro within 24 h could vary considerably from one sample source to another but not from lot to lot of the same source. All those results demonstrate that the initial state of conformation, oligomerization, and quality of the hIAPP can greatly impact the aggregation kinetics, and thus the information provided by these in vitro tests. Finally, a careful selection of the peptide batch and source is mandatory to perform relevant in vitro studies on hIAPP oligomerization and to screen new molecules modulating this pathological process.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available